Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial
Vianney Tricou, Xavier Sáez‐Llorens, Delia Yu, Luis Rivera, José Jimeno, Ana Cecilia Villarreal, Epiphany Dato, Onix Saldaña de Suman, Nathali Montenegro, Rodrigo DeAntonio, Sonia Mazara, Maria J. Vargas-Brochero, Debbie Mendoza, Martina Rauscher, Manja Brose, Inge Lefevre, Suely Tuboi, Astrid Borkowski, Derek Wallace
Topics & Concepts
MedicineDengue vaccineSerostatusImmunogenicityPlaceboDengue feverAdverse effectBooster doseClinical endpointInternal medicineClinical trialPediatricsDengue virusImmunologyViral loadAntibodyHuman immunodeficiency virus (HIV)ImmunizationPathologyAlternative medicineMosquito-borne diseases and controlViral Infections and Outbreaks ResearchParasitic Diseases Research and Treatment